Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

[1]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[2]  A. Eggermont,et al.  Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Aamdal,et al.  Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.

[4]  J. Kirkwood,et al.  Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[6]  A. Hauschild,et al.  EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .

[7]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[8]  Alexander D. MacKerell,et al.  Design of Inhibitors for S100B. , 2005, Current topics in medicinal chemistry.

[9]  O. Nieweg,et al.  Significance of serum S‐100B in melanoma patients before and after sentinel node biopsy , 2005, Journal of surgical oncology.

[10]  A. Hart,et al.  Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. , 2005, European journal of cancer.

[11]  R. Harpio,et al.  S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. , 2004, Clinical biochemistry.

[12]  H. Schmidt,et al.  S100&bgr; protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma , 2004, Melanoma research.

[13]  G. D. de Gast,et al.  Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma , 2003, Melanoma research.

[14]  A. Eggermont,et al.  On the release and half‐life of S100B protein in the peripheral blood of melanoma patients , 2001, International journal of cancer.

[15]  L. Hansson,et al.  Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Donato,et al.  Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. , 1999, Biochimica et biophysica acta.

[17]  A. Hauschild,et al.  S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma , 1999, Oncology.

[18]  C. Heizmann,et al.  Calcium regulation of Ndr protein kinase mediated by S100 calcium‐binding proteins , 1998, The EMBO journal.

[19]  B. Stoffel‐Wagner,et al.  Clinical significance of serum S100 in metastatic malignant melanoma. , 1995, European journal of cancer.

[20]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Cochran,et al.  S‐100 PROTEIN AS A MARKER FOR MELANOCYTIC AND OTHER TUMOURS , 1985, Pathology.

[22]  R. Gaynor,et al.  Detection of S‐100 protein as an aid to the identification of melanocytic tumors , 1982, International journal of cancer.

[23]  R. Gaynor,et al.  S100 protein is present in cultured human malignant melanomas , 1980, Nature.